MintNeuro Secures Major Funding to Transform Neural Devices
Multi-million-pound funding to drive development of next-gen neural implant technologies for clinical use.
MintNeuro, a trailblazer in scalable, low-power semiconductor technology for minimally invasive neural implants, has achieved a significant milestone by receiving funding to propel its innovative projects forward. Recently, MintNeuro was awarded three prestigious funding contracts from the UK government's Advanced Research and Invention Agency (ARIA), joining forces with leading academic institutions. The total funding, amounting to £17 million, is aimed at supporting the development of breakthrough chip-scale neurotechnologies, facilitating their integration into clinical practice. This remarkable support is part of ARIA's £69 million Precision Neurotechnologies programme, directed by Jacques Carolan.
Strategic Developments in Neurotechnology
Leading the charge, MintNeuro is set to oversee the tailored development and integration of low-power, function-specific integrated circuits for each of the three funded initiatives. Each project aligns perfectly with the mission of producing precise, less invasive, and biologically integrated neurotechnologies that hold great promise for enhancing medical treatments.
Precision 4D Control of Cortical Circuit Function
Under the leadership of Andrew Jackson from Newcastle University and MintNeuro, the first project, involving £8.2 million of the funding, focuses on advancing AI-driven, data-centric brain stimulation technology. Collaborating with prominent teams from universities such as Oxford and Imperial College London, this initiative seeks to define and accurately target functionally relevant neural populations in cortical circuits. By harnessing multi-modal machine learning combined with sophisticated stimulation techniques, this project aims to achieve 4D control over brain activity. The implications of this research extend to creating better treatment strategies for existing neurological conditions, including epilepsy and Parkinson's disease, as well as emerging applications such as stroke recovery and depression management.
Brain Mesh: A Distributed Network Interface
Next, led by Jacob Robinson from Motif Neurotech at Rice University, the £4.7 million 'Brain Mesh' project aims to develop a distributed network of ultra-compact, wireless neural implants. This network comprises millimeter-sized devices designed to sense neural signals and deliver fine-tuned stimulation across a wide range of brain functions. The innovative Brain Mesh architecture promises to offer a more comprehensive and accurate engagement with the brain compared to traditional implant systems, paving the way for advanced neuromodulation therapies targeting mental health disorders such as severe depression.
Minimally Invasive Stimulation Technology
The third initiative, spearheaded by Nir Grossman at the UK Dementia Research Institute at Imperial College London, involves a £4.1 million investment to develop a minimally invasive brain stimulation technology that can accurately modulate activity across various brain regions. This project is focused on multiplexed temporal interference stimulation, which allows changes in neural circuits without the need for surgical intervention. The goal is to create prototypes that refine this stimulation technique and demonstrate its efficacy. This innovative approach could foster new avenues of treatment for a variety of neurological and psychiatric conditions.
Leadership and Vision of MintNeuro
Jacques Carolan, Programme Director at ARIA, highlighted MintNeuro's central role in these key projects, praising the company for its high standards and innovative prowess. MintNeuro Co-Founder and CEO Dorian Haci expressed enthusiasm about the funding, noting that ARIA's programme unites innovative technologies that aim to offer groundbreaking solutions for some of the most challenging medical conditions. With the focus on disorders like epilepsy and Parkinson's disease, Haci emphasized the potential enhanced impact these projects could have.
MintNeuro Co-Founder and CTO Tim Constandinou added that their modular integrated circuit platform serves as a solid foundation for efficient and less invasive neural interfaces. The excitement surrounding these initiatives is rooted in MintNeuro's commitment to pushing the frontiers of neural interface technology.
Specializing at the intersection of neurotechnology and semiconductor innovation, MintNeuro is making strides in the field by developing advanced integrated circuits that cater to the future of neural implants. Their rich experience in chip design enables them to provide rapid and tailored solutions for medical device creators, fostering an environment where groundbreaking ideas can flourish.
Frequently Asked Questions
What is the significance of the ARIA funding for MintNeuro?
The ARIA funding, totaling £17 million, supports groundbreaking projects in neural technology, enhancing advancements in clinical applications.
What areas of neurological treatment will these projects impact?
The funded projects aim to improve treatments for epilepsy, Parkinson's disease, depression, and other neurological disorders.
How does MintNeuro's technology differ from traditional neural implants?
MintNeuro's technology focuses on creating less invasive, modular, and low-power solutions compared to conventional implant systems.
Who are the key collaborators in MintNeuro's projects?
MintNeuro collaborates with esteemed institutions like Newcastle University, Imperial College London, and Rice University.
What potential does the Brain Mesh project hold for mental health?
The Brain Mesh project is designed to offer precise neuromodulation for mental health disorders, enhancing treatment effectiveness significantly.
